Resultado de búsqueda
Hace 4 días · Catalyst Pharmaceuticals' new Chief Executive, Richard Daly, is no stranger to working at big companies.But after cutting his teeth at Big Pharma stalwarts, including Takeda Pharmaceutical and ...
Hace 5 días · Reaffirm Full Year 2024 Total Revenue Guidance Between $455 Million and $475 Million. Conference Call and Webcast to be Held on May 9, 2024, at 8:30 AM ET. CORAL GABLES, Fla., May 08, 2024 (GLOBE ...
Hace 5 días · Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of ...
Hace 5 días · CORAL GABLES, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2024 and ...
Hace 5 días · Our strong performance in the first quarter provides us with the momentum for continued growth throughout the year, stated Richard Daly, President and Chief Executive Officer of Catalyst. The successful U.S. launch of AGAMREE and sustained double-digit growth of FIRDAPSE are a testament to our team's commitment to serving patients through innovative products and outstanding execution.
Hace 2 días · #churchonlineservice #worship #praise #God #onlineworship #Christian #prayer #family #prayer #faithful CONTACT US:We look forward to hearing from you: https...
Hace 2 días · New CPRX CEO Richard Daly is interviewed by IBD at investors.com. Pipeline discussion includes 3 rare disease, orphan drugs—Firdapse for treatment of neuromuscular conditions in small cell lung cancer patients, Fycompa for epilepsy and newly licensed Agamree with an NDA filed by partner Santhera for Duchenne muscular dystrophy.
